Results suggest that 7.0 mg/kg ciclosporin once daily in food or per os for 6 weeks is effective and well tolerated in feline HD.

This study investigated the efficacy and safety of masitinib, a selective tyrosine kinase inhibitor capable of downregulating mast cell functions, for treatment of canine atopic dermatitis (CAD). Dogs with confirmed CAD received masitinib at 12.5 mg/kg/day (n = 202) or control (n = 104) for 12 weeks. A reduction in CAD Extent and Severity Index (CADESI-02) score of ≥ 50% at week 12 was observed in 61% of masitinib-treated dogs versus 35% of control dogs (P < 0.001), according to the modified intent-to-treat population. For dogs resistant to ciclosporin and/or corticosteroids (60% of the study population), CADESI-02 response rates were 60 versus 31%, respectively (P = 0.004). The mean reduction in pruritus score of severely pruritic dogs was 46 versus 29%, respectively (P = 0.045). Furthermore, 65% of owners with severely pruritic dogs assessed masitinib efficacy as good/excellent versus 35% control (P = 0.05). Overall, 63% of investigators assessed masitinib efficacy as good/excellent versus 35% control (P < 0.001). Premature discontinuations from the modified intent-to-treat population (28.2% masitinib versus 26.0% control) were mainly due to adverse events (13.4 versus 4.8%, respectively) or lack of efficacy (12.4 versus 18.3%, respectively). In total, 13.2% dogs presented with severe adverse events (16.0% masitinib versus 7.7% control). Masitinib showed a risk of reversible protein loss, although regular surveillance of blood albumin and proteinuria allowed for discontinuation of treatment while the dog was still clinically asymptomatic. Masitinib proved to be an effective and mostly well-tolerated treatment of CAD, including severe and refractory cases, with medically manageable adverse effects.

In humans with pemphigus foliaceus (PF), pathogenic autoantibodies are principally of IgG4 subclass and they cause superficial vesiculation when injected into neonatal mice. The objectives of this study were to determine the isotypes of circulating antikeratinocyte antibodies in dogs with PF, to assess whether serum antikeratinocyte antibody titres decreased during successful treatment, and to study whether such antibodies were pathogenic in passive transfers. Using indirect immunofluorescence with neonatal mouse skin substrates, circulating antikeratinocyte IgG antibodies were detected in 36 of 44 dogs with PF (82%). Serum autoantibodies belonged predominantly to IgG4 (three of 44; 80%) and IgG1 (30 of 44; 68%) subclasses. Antikeratinocyte IgG antibodies were detected in 16 of 20 normal dogs (80%), and these antibodies were IgG1 (16 of 20, 80%) but rarely IgG4 (two of 20; 10%) isotypes. In four dogs, IgG4 antikeratinocyte antibody titres decreased concomitantly to lesions nearing or reaching complete remission. In contrast, IgG or IgG1 titres remained stable or increased when lesions abated. Antikeratinocyte antibodies targeted mainly intercellular autoantigen(s) in the stratum granulosum, while in fewer dogs, such antibodies bound to cytoplasmic basal antigen(s). Intradermal injections of PF or pemphigus vulgaris (PV) IgG into neonatal mice caused subgranular or suprabasal acantholytic vesiculation without granulocyte infiltration, respectively. Similar transfers of normal dog IgG did not cause vesiculation. These observations suggest that antikeratinocyte IgG4 antibodies could be relevant to disease pathogenesis. Importantly, canine PF or PV IgG appear to be pathogenic when transferred passively into mice, causing vesiculation at epidermal levels similar to those of the natural disease.

Percutaneous application of 6 mg/mL glycerinated histamine solution, 50% glycerosaline solution and 0.9% buffered saline produced similar positive and negative control wheals. These observations warrant further studies of percutaneous allergen testing in cats with hypersensitivity dermatitis.

Abstract— In a blinded trial to determine the efficacy of potentiated sulfa drugs in the treatment of canine pyoderma, 50 dogs with superficial pyoderma were randomly assigned to receive either once or twice daily trimethoprim‐sulfadiazine (30mg.kg‐1) or once daily sulfadimethoxine‐ormetoprim (55mg.kg‐1 on the first day, then 27.5 mg.kg‐1 thereafter). Dogs were evaluated prior to antibiotic therapy. Clinical efficacy of the antibiotic was assessed after 3 weeks of antibiotic therapy and, if needed, after 6 weeks of antibiotic therapy. Forty‐five dogs completed the study; 43 dogs were used in the statistical analysis. The percentage of dogs that were cured of their pyoderma with once daily trimethoprim‐sulfadiazine was 38.5% by 3 weeks and 75.9% by 6 weeks. With twice daily trimethoprim‐sulfadiazine, 57.1 and 78.6% of dogs were cured by 3 and 6 weeks, respectively. With once daily sulfadimethoxine‐ormetoprim, 75.0 and 100% of dogs were cured by 3 and 6 weeks, respectively. This difference was not statistically significant, possibly due to the low sample size. Few adverse effects were noted. Résumé— Dans une étude en double aveugle pour apprécier l'efficacité des sulfamides potentialisés dans le traitement des pyodermites canines, cinquante chiens présentant une pyodermite superficielle ont reçu, au hasard, soit deux fois ou une fois par jour du triméthoprime‐sulfadiazine (30 mg.kg‐1) ou une fois par jour du sulfadiméthoxine‐ormétoprime (55mg.kg‐1 le premier jour, puis 27.5 mg.kg‐1). Les chiens ont étéévalués avant le traitement. L'efficacité clinique de l'antibiotique a été appréciée après 3 semaines de traitement et, si besion est, après 6 semaines. Le pourcentage de chiens guéris avec une prise quotidienne de triméthoprime‐sulfadiazine était de 33.5%à 3 semaines et 75.9%à 6 semaines. Avec des prises biquotidiennes de triméthoprime‐sulfadiazine 57.1% et 78.6% des chiens étaint guéris à 3 et 6 semaines. Avec une prise quotidienne de sulfadiméthoxine‐ormétoprime, 75.0% et 100.0% des chiens étaient guéris à 3 et 6 semaines. Cette différence n'était pais statistiquement significative, probablement à cause de la taille trop faible de l'échantilon. Très peu d'effects secondaires ont été notés. Zusammenfassung— Für eine Blindstudie zur Bestimmung der Wirksamkeit von potenzierten Sulfonamidpräparaten bei der Behandlung kaniner Pyrodermie wurden 50 Hunde mit oberflächlicher Pyodermie zufällig ausgewählt, um entweder einmal oder zweimal täglich Trimethoprim‐Sulfadiazin (30mg/kg) oder einmal täglich Sulfadimethoxin‐Ormetoprim zu erhalten (55 mg/kg am ersten Tag, danach 27,5 mg/kg). Die Hunde wurden vor der antibotischen Therapie untersucht. Die klinische Wirksamkeit der Antibiose wurde nach 3 Wochen antibiotischer Therapie und, wenn nötig, nach 6 Wochen antibiotischer Therapie ausgewertet. 45 Hunde durchliefen die Studie vollständig; 43 Hunde fanden in die statistische Analyse Eingang. Der Prozentsatz der Hunde, deren Pyrodermie durch einmal tägliches Trimethoprim‐Sulfadiazin geheilt wurde, lag bei 38,5% nach 3 Wochen und b...